23428-77-5

Basic information

• Product Name: Ethanone, 1-[4-Methoxy-3-(phenylMethoxy)phenyl]-
• Synonyms: Ethanone, 1-[4-Methoxy-3-(phenylMethoxy)phenyl]-;1-(3-(Benzyloxy)-4-methoxyphenyl)ethanone
• CAS NO: 23428-77-5
• Molecular Formula: C₁₆H₁₆O₃
• Molecular Weight: 256.29644
• Mol File: 23428-77-5.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Ethanone, 1-[4-Methoxy-3-(phenylMethoxy)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-[4-Methoxy-3-(phenylMethoxy)phenyl]-(23428-77-5)
• EPA Substance Registry System: Ethanone, 1-[4-Methoxy-3-(phenylMethoxy)phenyl]-(23428-77-5)

Safety Data

• Hazardous Substances Data: 23428-77-5(Hazardous Substances Data)

Usage

General Description

Ethanone, 1-[4-Methoxy-3-(phenylMethoxy)phenyl]-, also known as EMDT, is an organic compound with the molecular formula C16H16O4. It is a member of the ketone family and is commonly used in the field of organic synthesis. EMDT is a white to off-white crystalline powder and is soluble in organic solvents. It is often used as a building block in the synthesis of pharmaceuticals and other organic compounds. EMDT has also been studied for its potential pharmacological properties, including its potential as an anti-cancer agent.

Upstream product

• 6100-74-9 3-hydroxy-4-methoxyacetophenone 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 621-59-0 isovanillin 
• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 
• 6346-05-0 3-benzyloxy-4-methoxybenzaldehyde 
• 154490-49-0 1-(3-benzyloxy-4-methoxyphenyl)ethanol 

Downstream Products

• 77513-51-0 ethyl 2-(3-benzyloxy-4-methoxybenzoyl) acetate 
• 162290-05-3 (+/-)-7,3'-dihydroxy-4'-methoxyflavan 
• 1071152-63-0 (2,10-Bis-benzyloxy-3,9,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl)-methyl-amine 
• 160518-23-0 2,10-Bis-benzyloxy-3,9,11-trimethoxy-6,7-dihydro-dibenzo[a,c]cyclohepten-5-one 
• 160518-19-4 5-{3-[4-(tert-Butyl-dimethyl-silanyloxy)-3,5-dimethoxy-phenyl]-1-hydroxy-propyl}-2-methoxy-phenol 
• 162442-15-1 1-(3-hydroxy-4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)-1-propanone 
• 143702-43-6 5-[1-Hydroxy-3-(3,4,5-trimethoxy-phenyl)-propyl]-2-methoxy-phenol 
• 162442-14-0 (E)-1-(3-Benzyloxy-4-methoxy-phenyl)-3-(3,4,5-trimethoxy-phenyl)-propenone 
• 154490-50-3 3'-benzyloxy-3,4,4'-trimethoxy-chalcone 
• 23428-78-6 4-[(3-benzyloxy-4-methoxy-phenyl)-thioacetyl]-morpholine 

Relevant articles and documents

Identification of Interleukin-8-Reducing Lead Compounds Based on SAR Studies on Dihydrochalcone-Related Compounds in Human Gingival Fibroblasts (HGF-1 cells) in Vitro

Background: In order to identify potential activities against periodontal diseases, eighteen dihydrochalcones and structurally related compounds were tested in an established biological in vitro cell model of periodontal inflammation using human gingival fibroblasts (HGF-1 cells). Methods: Subsequently to co-incubation of HGF-1 cells with a bacterial endotoxin (Porphyromonas gingivalis lipopolysaccharide, pgLPS) and each individual dihydrochalcone in a concentration range of 1 μM to 100 μM, gene expression of interleukin-8 (IL-8) was determined by qPCR and cellular interleukin-8 (IL-8) release by ELISA. Results: Structure–activity analysis based on the dihydrochalcone backbone and various substitution patterns at its aromatic ring revealed moieties 20,4,40,60-tetrahydroxy 3-methoxydihydrochalcone (7) to be the most effective anti-inflammatory compound, reducing the pgLPS-induced IL-8 release concentration between 1 μM and 100 μM up to 94%. In general, a 2,4,6-trihydroxy substitution at the A-ring and concomitant vanilloyl (4-hydroxy-3-methoxy) pattern at the B-ring revealed to be preferable for IL-8 release inhibition. Furthermore, the introduction of an electronegative atom in the A,B-linker chain led to an increased anti-inflammatory activity, shown by the potency of 4-hydroxybenzoic acid N-vanillylamide (13). Conclusions: Our data may be feasible to be used for further lead structure designs for the development of potent anti-inflammatory additives in oral care products.

CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS

The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.

Synthesis of N-Substituted Condensed Tetrahydropyridine-Based Enaminones via Palladium-Catalyzed Intramolecular C–N Cross-coupling

A number of β-enaminones with secondary amino group (alkyl, cyclopropyl, and aryl) were prepared from corresponding β-diketones. Two general protocols for their palladium-catalyzed intramolecular C–N cross-coupling were established to give corresponding N-substituted condensed tetrahydropyridines in good yields. The methodology is applicable for a wide variety of structural motifs. The work also extends the applicability of novel, recently established, palladium precatalysts to new substrates.